REG - Spectral MD Holdings - Notice of AGM

Spectral MD HoldingsAnnouncement

01/09/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220901:nRSA8473Xa&default-theme=true

RNS Number : 8473X  Spectral MD Holdings, Ltd.  01 September 2022

 

Spectral MD Holdings, Ltd

("Spectral MD" or the "Company")

 

Notice of AGM

Proposed new 2022 Long Term Incentive Plan

 

LONDON, U.K AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a
predictive analytics company with proprietary AI and optical technology for
faster and more accurate treatment decisions in wound care, announces that the
Notice of Annual General Meeting ("AGM") and Form of Proxy will shortly be
available on the investors section of the Company's website here
(https://investors.spectralmd.com/) , and have been posted to shareholders who
have opted out of electronic communications.

 

Notice of AGM and Investor presentation

 

The Company's AGM will take place at 9.30 am (CT) and 3.30 pm (BST) on 27
September 2022 and will be held as a hybrid meeting electronically, via the
Investor Meet Company platform ("IMC") and physically, at the Company's
corporate headquarters located at 2515 McKinney Avenue, Suite 1000, Dallas, TX
75201.

 

Any shareholder wishing to attend in person must register in advance by
contacting the Company at spectralMD@walbrookpr.com.

 

The Company's CEO, Wensheng Fan, and CFO, Nils Windler, will also provide
shareholders with a short presentation after the formal business of the AGM
concludes and there will be an opportunity for investors to ask questions.
Investors can sign up to IMC for free and add to meet Spectral MD via:

 

https://www.investormeetcompany.com/spectral-md-holdings-ltd/register-investor
(https://www.investormeetcompany.com/spectral-md-holdings-ltd/register-investor)

 

Shareholders taking part via the IMC platform will not be able to speak or
vote on the AGM resolutions. Shareholders are therefore strongly encouraged to
exercise their voting rights by completing and submitting a Form of Proxy. It
is highly recommended that Shareholders submit their Form of Proxy as early as
possible to ensure that their votes are counted at the AGM.

 

Proposed 2022 Long Term Incentive Plan

 

A resolution will be proposed at the AGM seeking approval of the Company's new
2022 Long-Term Inventive Plan (the "2022 LTIP"). The 2022 LTIP is being
proposed upon the recommendation of the Company's Remuneration Committee and
has been designed to incentivise the Company's Executive Directors, certain
other Directors and other persons who provide services to the Company (the
"Participants").

 

Pursuant to the terms of the 2022 LTIP, the maximum aggregate number of shares
that may be issued to Participants under the 2022 LTIP is 20,000,000.
Furthermore, options granted pursuant to the 2022 LTIP shall be exercisable at
such time or times, or upon such event or events, and subject to such terms,
conditions, performance criteria and restrictions as shall be determined by
the Remuneration Committee or any other committee or subcommittee of the Board
duly appointed to administer the 2022 LTIP.

 

The 2022 LTIP is disclosed in full as Exhibit B of the Notice of AGM.

 

Related Party Transaction

 

The implementation of the 2022 LTIP (subject to the passing of the resolution
at the Company's AGM) will constitute a related party transaction pursuant to
rule 13 of the AIM Rules for Companies. Gerry Beaney, an Independent
Non-Executive Director of the Company, who will not participate in any awards
under the 2022 LTIP and is therefore an independent director for these
purposes, having consulted with the Company's Nominated Adviser, considers the
terms of the 2022 LTIP to be fair and reasonable insofar as Spectral MD's
shareholders are concerned.

 

Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018 ('MAR'). Upon the publication of this
announcement via Regulatory Information Service ('RIS'), this inside
information is now considered to be in the public domain.

 

 

For further information please contact:

 

 Spectral MD Holdings, Ltd.                                                      investors.spectralmd.com
 Wensheng Fan, Chief Executive Officer                                           via Walbrook PR
 Nils Windler, Chief Financial Officer

 SP Angel Corporate Finance LLP (NOMAD and Joint Broker)                         Tel: +44 (0)20 3470 0470
 Stuart Gledhill/Caroline Rowe (Corporate Finance)

 Vadim Alexandre/Rob Rees (Sales & Broking)

 Stifel Nicolaus Europe Limited (Joint Broker)                                   Tel: +44 (0)20 7710 7600

 Charles Hoare / Ben Maddison / Nick Harland /

 Will Palmer-Brown

 Walbrook PR Ltd (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com
 Paul McManus / Louis Ashe-Jepson                  Mob: +44 (0)7980 541 893 / +44 (0)7747 515 393

 Alice Woodings                                    +44 (0)7407 804 654

 

 

About Spectral MD:
 

We are a dedicated team of forward-thinkers striving to revolutionize the
management of wound care by "Seeing the Unknown" ® with our DeepView(®)
Wound Imaging System.

www.spectralmd.com

info@spectralmd.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOASDLFUFEESEDA